BioNTech SE (ETR:22UA)
Germany
· Delayed Price · Currency is EUR 82.60
-0.30 (-0.36%)
At close: Dec 5, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| COVID-19 Vaccine Revenue (Post-FY2023 Reporting) | 2.43B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| COVID-19 Vaccine Revenue (Post-FY2023 Reporting) Growth | -18.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Sales Revenue (Post-FY2023 Reporting) | 319.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Sales Revenue (Post-FY2023 Reporting) Growth | 6.60% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Research & Development | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Research & Development Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Sales Revenue (Pre-FY2024 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Sales Revenue (Pre-FY2024 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| COVID-19 Vaccine Revenue (Pre-FY2024 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| COVID-19 Vaccine Revenue (Pre-FY2024 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|